Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 18, 2015, Pages 5679-5684

  Nair, Pradeep M ^a   Flores, Heather ^a   Gogineni, Alvin ^a   Marsters, Scot ^a   Lawrence, David A ^a   Kelley, Robert F ^a   Ngu, Hai ^a   Sagolla, Meredith ^a   Komuves, Laszlo ^a   Bourgon, Richard ^a   Settleman, Jeffrey ^a   Ashkenazi, Avi ^a  

^a GENENTECH INC   (United States)

Author keywords

Apoptosis; Caspase; Cell death; Death receptor; Membrane display

Indexed keywords

ANTINEOPLASTIC AGENT; NANOSPHERE; RECOMBINANT APOLIPOPROTEIN 2; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CASPASE; CASPASE 8; CD70 ANTIGEN; EPITOPE; FAS LIGAND; FASLG PROTEIN, HUMAN; LIGAND; LIPOSOME; RECOMBINANT PROTEIN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL DEATH; CELL SURFACE; CROSS LINKING; CYTOTOXICITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; HUMAN; IMMUNOCOMPETENT CELL; JURKAT CELL LINE; LIPID BILAYER; PRIORITY JOURNAL; SURFACE PROPERTY; ANIMAL; BIOTINYLATION; CANCER TRANSPLANTATION; CELL MEMBRANE; CHEMISTRY; FLUORESCENCE MICROSCOPY; IC50; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOUSE; NEOPLASM; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD70; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOTINYLATION; CASPASE 8; CASPASES; CELL LINE, TUMOR; CELL MEMBRANE; EPITOPES; FAS LIGAND PROTEIN; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; INHIBITORY CONCENTRATION 50; LIGANDS; LIPOSOMES; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84928964005     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1418962112     Document Type: Article

References (38)

1. Danial NN, Korsmeyer SJ (2004) Cell death: Critical control points. Cell 116(2):205-219.
2. Billard C (2013) BH3 mimetics: Status of the field and new developments. Mol Cancer Ther 12(9):1691-1700.
3. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2(6):420-430.
4. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8(10):782-798.
5. Cory S, Adams JM (2002) The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2(9):647-656.
6. Ashkenazi A, Dixit VM (1998) Death receptors: Signaling and modulation. Science 281(5381):1305-1308.
7. Wallach D, et al. (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17:331-367.
8. Siegel RM, et al. (2004) SPOTS: Signaling protein oligomeric transduction structures are early mediators of death receptor-induced apoptosis at the plasma membrane. J Cell Biol 167(4):735-744.
9. Wilson NS, Dixit V, Ashkenazi A (2009) Death receptor signal transducers: Nodes of coordination in immune signaling networks. Nat Immunol 10(4):348-355.
10. Soria J-C, et al. (2011) Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 29(33):4442-4451.
11. Yang A, Wilson NS, Ashkenazi A (2010) Proapoptotic DR4 and DR5 signaling in cancer cells: Toward clinical translation. Curr Opin Cell Biol 22(6):837-844.
12. Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7(12):1001-1012.
13. Ashkenazi A, Holland P, Eckhardt SG (2008) Ligand-based targeting of apoptosis in cancer: The potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26(21):3621-3630.
14. Holland PM (2014) Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev 25(2):185-193.
15. Subbiah V, et al. (2012) Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulanermin), a dual proapoptotic receptor (DR4/DR5) agonist. Mol Cancer Ther 11(11):2541-2546.
16. Herbst RS, et al. (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28(17):2839-2846.
17. Kelley SK, et al. (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299(1):31-38.
18. Ashkenazi A (2015) Targeting the extrinsic apoptotic pathway in cancer: Lessons learned and future directions. J Clin Invest 125(2):487-489.
19. Lawrence D, et al. (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7(4):383-385.
20. Wilson NS, et al. (2012) Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth. Cancer Cell 22(1):80-90.
21. Seifert O, et al. (2014) Tetravalent antibody-scTRAIL fusion proteins with improved properties. Mol Cancer Ther 13(1):101-111.
22. Gieffers C, et al. (2013) APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors. Mol Cancer Ther 12(12):2735-2747.
23. Hymowitz SG, et al. (1999) Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 4(4):563-571.
24. Kelley RF, et al. (2005) Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280(3):2205-2212.
25. Salaita K, et al. (2010) Restriction of receptor movement alters cellular response: Physical force sensing by EphA2. Science 327(5971):1380-1385.
26. Nair PM, Salaita K, Petit RS, Groves JT (2011) Using patterned supported lipid membranes to investigate the role of receptor organization in intercellular signaling. Nat Protoc 6(4):523-539.
27. Mossman KD, Campi G, Groves JT, Dustin ML (2005) Altered TCR signaling from geometrically repatterned immunological synapses. Science 310(5751):1191-1193.
28. Gonzalvez F, et al. (2012) TRAF2 sets a threshold for extrinsic apoptosis by tagging caspase-8 with a ubiquitin shutoff timer. Mol Cell 48(6):888-899.
29. Humphries JD, Byron A, Humphries MJ (2006) Integrin ligands at a glance. J Cell Sci 119(Pt 19):3901-3903.
30. De Miguel D, et al. (2013) Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells. Mol Pharm 10(3):893-904.
31. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 65(1):36-48.
32. Chang H-I, Yeh M-K (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 7:49-60.
33. Ashkenazi A, et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104(2):155-162.
34. Hylander BL, et al. (2005) The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3(1):22.
35. Walczak H, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5(2):157-163.
36. Wilson NS, et al. (2011) An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19(1):101-113.
37. Graves JD, et al. (2014) Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 26(2):177-189.
38. Park JW (2002) Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4(3):95-99.